Gilead Sciences (NASDAQ:GILD) and licensor Galapagos NV (NASDAQ:GLPG) announce long-term results from Phase 3 clinical trials, FINCH 1 and FINCH 2, evaluating JAK1 inhibitor filgotinib in patients with moderately-to-severely active rheumatoid arthritis (RA).
Data at week 52 are consistent with the safety,
tolerability and efficacy results observed at weeks 12 and 24. Detailed
results will be presented at a future medical conference.
Marketing applications are currently under review
in Europe and Japan. Gilead plans to file an NDA in the U.S. later this
quarter.
GILD is up 1% and GLPG is up 2% premarket, both on light volume.
https://seekingalpha.com/news/3505212-gilead-galapagos-filgotinib-shows-durable-effect-late-stage-ra-studies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.